Investor Presentaiton
Investor Presentation
First nine months of 2018
Slide 39
Region Japan & Korea at a glance
Diabetes market by value and
Novo Nordisk market share
Diabetes trend in population
Million
16
Population with diabetes
Diabetes growth rate
NN Insulin MS
NN OAD MS
bDKK
40
Novo Nordisk reported sales
NN GLP-1 MS
First nine months of
2018
Sales
(mDKK)
YTD
growth²
80%
Long-acting insulin³
637
4%
9%
0%
>
Premix insulin4
483
(1%)
I
12
30
27.6%¹
nsum
60%
Fast-acting insulin5
578
(13%)
12
12
11
Human insulin
140
(17%)
8
(3.1%)¹
20
40%
Total insulin
1,838
(5%)
GLP-16
440
7%
4.2%¹
Other diabetes care?
274
0%
10
- 20%
OAD
Diabetes care
2,552
(3%)
Obesity (SaxendaⓇ)
72
0
2000
2017
2045
Aug
2013
0%
Biopharm³
1,563
(7%)
Aug
2018
Total
4,187
(3%)
Japan & Korea population 2018: ~0.2 billion people and diabetes
prevalence ~8.0%
Source: International Diabetes Federation: Diabetes Atlas 1th Edition
2000 and Diabetes Atlas 8th Edition 2017
1 CAGR calculated for last 5-year period
Competitor value market share for insulin as of Aug 2018: Eli Lilly
22% and Sanofi 21%
Competitor value market share for GLP-1 as of Aug 2018: Eli Lilly 59%
and AstraZeneca 4%
OAD: Oral anti-diabetic; MS: Market share
Source: IQVIA MAT Aug, 2018 value figures
2 Percentage change in local currency from YTD Q3 2017 to YTD Q3 2018
3 Comprises TresibaⓇ and Levemir®; 4 Comprises NovoMix® and
RyzodegⓇ 5 Comprises NovoRapid®; 6 Comprises VictozaⓇ; 7 Comprises
NovoNormⓇ and needles; 8 Comprises primarily NovoSevenⓇ,
NovoEight® NovoThirteenⓇ and NorditropinⓇView entire presentation